Cabozantinib

Generic Name: Cabozantinib

Brand Names: Cabometyx, Cometriq

Drug Type: Small Molecule

Chemical Formula: C_₂₈H_₂₄FN_₃O_₅

CAS Number: 849217-68-1

Unique Ingredient Identifier: 1C39JW444G

Background: Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formu...

Indication: ⑴治疗进展的、不能切除的局部晚期或转移的髓性甲状腺癌。

⑵用于舒尼替尼（索坦）治疗失败的晚期肾癌。

Associated Conditions: Advanced Renal Cell Carcinoma, Hepatocellular Carcinoma, Metastatic Differentiated Thyroid Cancer, Locally advanced Differentiated Thyroid Cancer (DTC), Metastatic Clear Cell Renal Cell Carcinoma (ccRCC), Progressive, metastatic Medullary thyroid cancer

Associated Therapies: -

Clinical Trials

Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies

Phase 1

Active, not recruiting

Conditions: Esophageal Adenocarcinoma
Gastric Cancer
Hepatocellular Carcinoma
Colorectal Cancer

Interventions: Drug: Cabozantinib
Drug: Durvalumab
Drug: Tremelimumab

First Posted Date: 2018-05-29

Last Posted Date: 2024-06-07

Lead Sponsor: Anwaar Saeed

Target Recruit Count: 117

Registration Number: NCT03539822

Locations: 🇺🇸
University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma

Phase 2

Completed

Conditions: Bladder Cancer
Metastatic Urothelial Carcinoma

Interventions: Drug: Cabozantinib
Drug: Pembrolizumab

First Posted Date: 2018-05-23

Last Posted Date: 2024-11-26

Lead Sponsor: University of Utah

Target Recruit Count: 37

Registration Number: NCT03534804

Locations: 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States

Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Recurrent Lung Non-Squamous Non-Small Cell Carcinoma
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
Stage IV Lung Non-Small Cell Cancer AJCC v7

Interventions: Biological: Nivolumab
Drug: Cabozantinib
Biological: Ipilimumab

First Posted Date: 2018-03-19

Last Posted Date: 2023-10-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 3

Registration Number: NCT03468985

Locations: 🇺🇸
Riverside Methodist Hospital, Columbus, Ohio, United States
🇺🇸
Grant Medical Center, Columbus, Ohio, United States
🇺🇸
The Mark H Zangmeister Center, Columbus, Ohio, United States

and more 465 locations

Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer

Phase 2

Active, not recruiting

Conditions: Metastatic Head and Neck Carcinoma
Paranasal Sinus Squamous Cell Carcinoma
Recurrent Head and Neck Squamous Cell Carcinoma
Recurrent Hypopharyngeal Squamous Cell Carcinoma
Recurrent Laryngeal Squamous Cell Carcinoma
Recurrent Oral Cavity Squamous Cell Carcinoma
Recurrent Oropharyngeal Squamous Cell Carcinoma
Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7
Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7

Interventions: Drug: Cabozantinib
Biological: Pembrolizumab

First Posted Date: 2018-03-16

Last Posted Date: 2023-05-09

Lead Sponsor: Emory University

Target Recruit Count: 36

Registration Number: NCT03468218

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States

CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma

Phase 2

Completed

Conditions: Advanced Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma

Interventions: Drug: CB-839
Drug: Cabozantinib
Drug: Placebo

First Posted Date: 2018-02-09

Last Posted Date: 2023-03-20

Lead Sponsor: Calithera Biosciences, Inc

Target Recruit Count: 444

Registration Number: NCT03428217

Locations: 🇺🇸
NorthShore University HealthSystem, Evanston, Illinois, United States
🇺🇸
Orchard Healthcare Research, Inc., Skokie, Illinois, United States
🇺🇸
University of Maryland, Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States

and more 129 locations

Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma

Phase 2

Completed

Conditions: Metastatic Carcinoma in the Adrenal Cortex
Stage III Adrenal Cortex Carcinoma AJCC v8
Stage IV Adrenal Cortex Carcinoma AJCC v8
Unresectable Adrenal Cortex Carcinoma

Interventions: Drug: Cabozantinib
Other: Pharmacogenomic Study
Other: Pharmacokinetic Study

First Posted Date: 2017-12-12

Last Posted Date: 2024-12-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 18

Registration Number: NCT03370718

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

caBozantinib in cOllectiNg ductS Renal Cell cArcInoma

Phase 2

Completed

Conditions: Collecting Duct Carcinoma (Kidney)

Interventions: Drug: cabozantinib

First Posted Date: 2017-11-28

Last Posted Date: 2021-05-10

Lead Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Target Recruit Count: 23

Registration Number: NCT03354884

Locations: 🇮🇹
Giuseppe Procopio, Milan, Italy

A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma

Phase 2

Completed

Conditions: Advanced Renal Cell Carcinoma

Interventions: Drug: Cabozantinib

First Posted Date: 2017-11-13

Last Posted Date: 2021-09-20

Lead Sponsor: Takeda

Target Recruit Count: 35

Registration Number: NCT03339219

Locations: 🇯🇵
Keio University Hospital, Shinjuku-ku, Tokyo, Japan
🇯🇵
Nagoya University Hospital, Nagoya, Aichi, Japan
🇯🇵
Kyushu University Hospital, Fukuoka, Japan

and more 16 locations